Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients

Summary

This study is specifically designed to determine whether the initiation of Myfortic 2 weeks prior to transplantation will enhance the therapeutic efficacy of Simulect induction therapy in low to moderate risk patients. Specifically, the addition of Myfortic pretransplant to Simulect induction will be compared to standard Myfortic therapy with Thymoglobulin induction starting at the time of transplant in kidney transplant recipients.

Timeline

Start

2010-09

Primary completion

2014-04

Completion

2014-04

Drugs

Indications